Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
18 Jul, 2025 (Friday)

            
ALPHAMAB-B(2160)
Analysis:
Alphamab Oncology (9966) possesses a robust proprietary technology platform in ADC (Antibody-Drug Conjugates), bispecific antibodies, and multifunctional protein engineering. Its mission is to provide innovative therapeutic biologics for patients worldwide by leveraging its unique drug discovery and development capabilities. The group’s highly differentiated internal pipeline consists of ADC, monoclonal antibody, and bispecific antibody oncology drugs at various stages of development, including one product approved for market by the National Medical Products Administration (NMPA) and several in Phase III or pivotal clinical trials.The group has advanced protein engineering capabilities for developing various protein building blocks (including single-domain antibodies (sdAb) and engineered proteins). Its proprietary platforms include sdAb, CRIB (Charge Repulsion Improves Bispecific) platform, glycan-specific conjugation platform, linker-payload platform, high-concentration subcutaneous formulation platform, and dual-payload platform based on glycan-specific conjugation. Additionally, the group is enhancing its state-of-the-art manufacturing capabilities by designing and constructing a new facility compliant with the current Good Manufacturing Practices (cGMP) standards of the NMPA, European Medicines Agency (EMA), and U.S. Food and Drug Administration (FDA), with an expected capacity exceeding 40,000 liters. A new production plant for drug substances and preparations of ADCs based on existing production capacity, is set to commence operations soon.In 2024, the group made significant progress in its drug product pipeline and business operations, including: KN035 (Envafolimab) received marketing approval from the Macau Drug Supervision Administration for the treatment of adult patients with unresectable or metastatic non-microsatellite instability-high (MSI-H)/non-mismatch repair deficient (dMMR) advanced solid tumors. Wholly-owned subsidiary Jiangsu Alphamab Biopharmaceuticals entered into a licensing agreement with 3D Medicines and Glenmark Specialty S.A., granting Glenmark exclusive rights and sublicensing for KN035 in oncology indications for development and commercialization in India, Asia-Pacific (excluding Singapore, Thailand, and Malaysia), the Middle East, Africa, Russia, CIS countries, and Latin America. Jiangsu Alphamab Pharmaceuticals signed a research and collaboration agreement with ArriVent BioPharma, Inc. to utilize Jiangsu Alphamab’s proprietary linker-payload platform (Alphatecan) and glycan-specific conjugation platform to discover and develop novel ADC products. Jiangsu Alphamab entered into a licensing agreement with Shanghai JMT-Bio Technology, valued up to RMB 3.08 billion, for the development, sale, supply, and commercialization of JSKN003 for oncology-related indications in mainland China. (I do not hold the aforementioned stock.)
Strategy:
Buy-in Price: $8.10, Target Price: $9.20, Cut Loss Price: $7.70


BILIBILI-W(9626)
Analysis:
This year, support for the overseas expansion of games from various fronts has been evident. In April, the State Council approved the Work Plan for Accelerating the Comprehensive Pilot Program for Expanding the Opening Up of the Service Sector, outlining 155 pilot tasks, among which the "overseas expansion" of games was highlighted. The document states that the country will fully advance the strategic upgrade of game exports, focusing on cultivating an internationalized full value chain for games that encompasses core segments such as IP incubation, content development, global publishing, and overseas localized operations. On July 11, the company hosted its 2025 Investor Day in Shanghai, where it shared insights with investors on topics including games, advertising, commercialization, and AI. Management emphasized its strategy centered on high-quality content, AI-empowered content and monetization, and long-lifecycle games. The continuous growth in platform user traffic serves as the foundation for sustained outperformance in advertising revenue; advertising demand in the gaming, content consumption, and e-commerce sectors remains very strong, with effective operations and AI technology enabling robust advertising growth under lighter workloads.
Strategy:
Buy-in Price: $191.90, Target Price: $211.00, Cut Loss Price: $173.00



Kuaishou (1024.HK) - AI-driven end-to-end efficiency improvement

Financial summary

Kuaishou is a leading content community and social platform in China and globally. As a technology company powered by and built upon artificial intelligence, Kuaishou is dedicated to continuously enriching its services and application scenarios through ongoing technological innovation and product upgrades, thereby creating value for its customers. On Kuaishou, users record and share their lives through short videos and live streaming, discover what they need, and showcase their talents. By closely collaborating with content creators and businesses, Kuaishou provides technologies, products, and services that meet users' diverse needs, including entertainment, online marketing services, e-commerce, local lifestyle services, gaming, and more.

Financial performance

In the first quarter of 2025, the company achieved total revenue of RMB 32.6 billion (Chinese yuan, same below), representing a year-over-year increase of 10.9%. In terms of profitability, operating profit reached RMB 4.3 billion, up 6.6% YoY, while adjusted net profit was RMB 4.6 billion, a 4.4% YoY increase. By segment, 1Q25 online marketing services revenue grew 8.0% YoY to RMB 18.0 billion, primarily driven by increased ad spending from marketing clients due to the adoption of AI-powered ad placement solutions. Live streaming revenue rose 14.4% YoY to RMB 9.8 billion, attributed to refined operations and diversified content. Other services revenue increased 15.2% YoY to RMB 4.8 billion, mainly fueled by e-commerce business growth.

In terms of expenses, the company’s sales and marketing expenses as a percentage of total revenue decreased to 30.4% in Q1 2025 from 31.9% in the same period last year, primarily due to improved operational efficiency.

In Q1 2025, Kuaishou’s average daily active users (DAUs) and monthly active users (MAUs) reached 408 million and 712 million, respectively, up 3.6% and 2.1% YoY. The app’s DAUs hit a record high and surpassed 400 million for the third consecutive quarter. Through refined user growth strategies, the average customer acquisition cost (CAC) for new users decreased. Meanwhile, enhanced content consumption experiences—driven by high-quality content, iterative traffic distribution mechanisms, and diverse community engagement features—further improved new user retention rates.

Online Marketing Services: External-loop business as the core growth engine, AI-driven end-to-end efficiency improvement

In the first quarter of 2025, external-loop marketing services served as the primary growth driver, with AI technology deeply enhancing end-to-end operational efficiency. Within the content consumption sector, marketing expenditure for short dramas achieved rapid year-over-year growth. Marketing clients leveraged native pathways to elevate content value and strengthen user engagement, deepening the platform’s understanding of user preferences. In the local lifestyle sector, solutions such as native direct messaging and lead form collection boosted conversion rates, driving marketing expenditure growth of over 50.0% YoY.

Meanwhile, AI technology empowered the entire workflow of online marketing service solutions, delivering efficient brand marketing and performance-driven conversions. According to management, Q2 online marketing service revenue is expected to return to double-digit YoY growth, with accelerated ad expenditure growth in the generalized shelf-based advertising space.

E-commerce: Tripartite Operating Model Drives Continuous Optimization Across Multiple Domains

The company continued to enhance consumers' shopping experience. In Q1 2025, e-commerce GMV grew by 15.4% YoY to RMB 332.3 billion, while the monthly active buyer count reached 135 million, up 7.1% YoY. By continuously developing growth resources and widely applying large-scale models, the company provided merchants with a full suite of AI-powered livestreaming tools, leading to a YoY increase of over 30.0% in new merchants joining Kuaishou during Q1 2025. Through the establishment of a tripartite operating model integrating "livestreaming + mall + short videos," the company drove continuous optimization across multiple domains. In Q1 2025, generalized shelf-based e-commerce contributed approximately 30.0% of total GMV, with the number of daily active merchants growing over 40.0% YoY, while short video-based e-commerce GMV surged by over 40.0% YoY.

Livestreaming: YoY Growth Returns to Positive Territory

The company further refined its operations in key categories such as multi-host livestreaming and group livestreaming. By the end of Q1 2025, the number of signed agencies increased by over 25.0% YoY, while the number of signed streamers grew by over 40.0% YoY.

Company valuation

In April 2025, the company launched Keling AI 2.0, introducing the innovative concept of multimodal vision-language and rolling out multimodal editing features, which have now been widely adopted across various industries including advertising marketing, short dramas, and smart devices. Leveraging AI technology, the company has empowered the entire process of online marketing service solutions, encompassing AIGC marketing material production, intelligent marketing placement agents, and large-scale marketing acompañrecommendation models, thereby enhancing clients' marketing conversion efficiency. In Q1 2025, the daily average ad spending on AIGC marketing materials reached approximately RMB 30 million.

Overall, we are optimistic about the company's medium-to-long-term growth prospects and believe its fair valuation should be 17 times the projected 2025 PE, corresponding to a target price of HK$73 per share. We forecast the company's 2025-2027 operating revenues at RMB 142.4/156.2/170.7 billion, with net profits of RMB 16.8/21.3/26.3 billion, translating to EPS of RMB 3.91/4.94/6.11. The current share price implies PE multiples of 15/12/10x for 2025-2027. In conclusion, we initiate coverage with an "Accumulate" rating.

Risk factors

1) Slower-than-exhibitspected progress in AI applications;
2) User growth slowdown;
3) Regulatory risks in the internet industry.

Financials

"財務資料"

Current Price as of: Jul 14 2025
Exchange rate: HKD/RMB = 0.91
Source: PSHK Est.

Download PDF version...




Writer Info
Megan Tao
(Research Analyst)
Tel: +852 2277 6515
Email:
megantao@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2025 Phillip Securities (HK) Ltd. All Rights Reserved.